HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT

Arslan, Fatma Demet; KURTULUŞ, Mustafa; GÜLEÇ, Rasime Derya; ÖZYILMAZ, Berk; köse, şükran

HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT

Rasime Derya GÜLEÇ, (Sağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi Doku Tipleme Laboratuvarı, İzmir, Türkiye)

Mustafa KURTULUŞ, (Sağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi Doku Tipleme Laboratuvarı, İzmir, Türkiye)

Fatma Demet ARSLAN, (Bakırçay Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, İzmir, Türkiye)

Berk ÖZYILMAZ, (Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, Tıp Anabilim Dalı Genetik İzmir, Türkiye)

Şükran KÖSE (Sağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi Enfeksiyon Anabilim Dalı Hastalıklar ve Klinik Mikrobiyoloji İzmir, Türkiye)

İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi

13 4

Yıl: 2022 Cilt: 26 Sayı: 3 Sayfa Aralığı: 249 - 254 Metin Dili: İngilizce İndeks Tarihi: 18-09-2022

HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT

Öz:

ntroduction: Human Leukocyte Antigen (HLA)-B*57:01 is associated with a hypersensitivity reaction to abacavir used in antiretroviral therapy in patients infected with human immunodeficiency virus (HIV)-1. In this study, we aimed to investigate the prevalence of HLA-B*57:01 and HLA-B alleles that may pose a risk in the Turkish population. Material and Methods: In this retrospective study, 500 HIV-1 infected patients who applied to the Tissue Typing Laboratory and 500 healthy bone marrow donors as the control group were examined. HLA-B genotyping was performed before starting abacavir therapy. 451 (90.2%) of HIV-1 positive patients and 264 (52.8%) control group were male (p<0.001). HLA-B genotyping was performed using the sequence-specific primer (SSP) HLA-B kit or the HLA-B sequence-specific oligonucleotide probe hybridization (SSO) kit. The presence or absence of the HLA- B*57:01 specific allele in individuals with B*57 allele was detected using the HLA-B*57:01 SSP kit. Result: The HLA-B*57:01 allele frequency was found to be 1.5% (n=15) in HIV-1 positive patients and 1.6% (n=16) in controls. The prevalence of HLA-B*57:01 allele in the Turkish population was calculated as 3.1% (n=31). Also HLA-B*7 (p=0.013, OR: 1.761), HLA-B*14 (p=0.016, OR: 2.592), HLA-B*18 (p=0.001, OR: 2.106), HLA-B* 49 (p=0.035, OR: 1.626) alleles were associated with susceptibility to HIV-1. Conclusion: The prevalence of HLA-B*57:01, which we found as 3.1% in our society, is lower than the Caucasian ethnic group (5-8%) . Our results will shed light on the cost-effectiveness analysis studies to be conducted on HLA B*57:01 screening in HIV-1 positive patients and will contribute to the literature.

Anahtar Kelime:

HIV-1 ENFEKTE TÜRK HASTALARINDA HLA-B VARYASYONLARI VE HLA-B*57:01 PREVALANSI

Öz:

Giriş: İnsan Lökosit Antijeni (HLA)-B*57:01, insan immün yetmezlik virüsü (HIV)-1 ile enfekte hastalarda antiretroviral tedavide kullanılan abakavire karşı gelişen hipersensitivite reaksiyonu ile ili şkilidir. Bu çalışmada, Türk popülasyonundaki HLA-B*57:01 prevalansının ve risk oluşturabilecek HLA-B alllelerinin ara ştırılması amaçlanmaktadır. Gereç ve Yöntemler: Bu retrospektif çal ışmada Doku Tipleme Laboratuvarına başvurmuş 500 HIV-1 ile enfekte hasta ve kontrol grubu olarak 500 sa ğlıklı kemik iliği donörü incelendi. Hastalara abakavir tedavisi ba şlamadan önce HLA-B genotiplemesi yapıldı. HIV-1 pozitif hastalar ın 451’i (%90.2), kontrol grubunun ise 264’ü (%52,8) erkekti (p<0.001). HLA-B genotiplemesi diziye özgül primer (SSP) HLA-B kiti veya HLA-B diziye özgül oligonükleotid prob hibridizasyon (SSO) kiti kullanılarak yapıldı. B*57 alleli saptanan bireylerde HLA-B*57:01 spesifik allelinin varlığı veya yokluğu HLA-B*57:01 SSP kiti kullanılarak tespit edildi. Bulgular: HLA-B*57:01 allel frekans ı HIV-1 pozitif hastalarda %1.5 (n=15) ve kontrollerde %1.6 (n=16) olarak bulundu. Türk toplumunun HLA-B*57:01 allel prevalansı %3.1 (n=31) olarak hesaplandı. Ayr ıca HLA-B*7 (p=0.013, OR: 1.761), HLA-B*14 (p=0.016, OR: 2.592), HLA-B*18 (p=0.001, OR: 2.106), HLA-B*49 (p=0.035, OR: 1.626) allelleri HIV-1 enfeksiyonuna duyarlılık ile ilişkiliydi. Sonuç: Toplumumuzda %3.1 olarak bulduğumuz HLA-B*57:01 prevalansı, popülasyon olarak dahil olduğumuz Kafkas etnik grubundan (%5-8) daha dü şüktür. Sonuçlar ımız HIV-1 pozitif hastalarda HLA B*57:01 taraması yapılması ile ilgili yapılacak maliyet-etkinlik analizi çalışmalarına ışık tutacak ve literatüre katkı sağlayacaktır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5(2): 203-11.
2. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. The Lancet 2002; 359 (9312): 1121-2.
3. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen, B et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical therapeutics 2001; 23(10): 1603-14.
4. Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B* 5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue antigens 2007; 70(1): 58-61.
5. Suwastini NKA, Wiraningsih P, Adnyani NLPS. An analysis of interlanguage among EFL students’ speech production in English microteaching class. Asian EFL Journal 2020; 27(4.5): 66-89.
6. Fan WL, Shiao MS, Hui RCY, Su SC, Wang CW, Chang YC et al. HLA association with drug-induced adverse reactions. Journal of immunology research 2017, 2017: 3186328.
7. Taylor M, Hussain A, Urayama K, Chokkalingam A, Thompson P, Trachtenberg E et al. The human major histocompatibility complex and childhood leukemia: An etiol ogical hypothesis based on molecular mimicry. Blood Cells, Molecules, and Disease 2009; 42(2): 129-35.
8. Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Annual review of medicine 2003; 54(1): 535-51.
9. Adland E, Paioni P, Thobakgale C, Laker L, Mori L, M uenchhoff M et al. Discordant impact of HLA on viral replicative capacity and disease progression in pediatric and adult HIV infection. PLoS pathogens 2015; 11(6): e1004954.
10. Kløverpris H, Harndahl M, Carlson J, Leslie A, van der Stok M, Huang G et al. HIV control through a single nucleotide on the HLA-I locus. Retrovirology 2012; 9(2): 1-1
11. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science, 1999; 283(5408): 1748-52.
12. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R et al. Effect of a single amino acid change in MHC Class I Molecules on the rate of progression to AIDS. N Engl J Med. 2001; 344(22): 1668-75.
13. Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome. A review of the literature examining associations with HLA. Hum Immunol. 1995; 44(3): 156-69.
14. Juarez-Molina CI, Valenzuela-Ponce H, Avila-Rios S, Garrido-Rodriguez D, Garcia-Tellez T, Soto-Nava M et al. Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico. Aids. 2014; 28(11): 1687-90.
15. Kaslow RA, Rivers C, Tang J, Bender TJ, Goepfert PA, El H abib R et al. Polymorphisms in HLA Class I Genes Associated with both favorable prognosis of Human Immunodeficiency Virus (HIV) Type 1 ınfection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV Recombinant Canarypox Vaccines. J Virol 2001; 75(18): 8681-9.
16. Zhang Y, Peng Y, Yan H, Xu K, Saito M, Wu H et al . Multilayered defense in HLA-B51–Associated HIV viral control. J Immunol 2011; 187(2): 684-91.
17. Shankarkumar U, Shankarkumar A. HLA – B 17 Prevalence in HIV-1 infected patients under antiretroviral treatment. International Journal of Human Genetics 2011; 11(1): 59-62.
18. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nature Reviews Immunology 2018; 18(5): 325- 39.
19. Pat ıroğlu T, Akar HH. The Frequency of HLA-A, HLA-B, and HLA-DRB1 Alleles in patients with acute lymphoblastic leukemia in the Turkish Population: A case-control study/akut lenfoblastik lösemili hastalarda HLA-A, HLA-B, ve HLA-DRB1 alellerinin Türk toplumundaki Sıklığı: olgu-kontrol çalısması. Turkish J Hematol. 2016; 33(4): 339-45.
20. Uçar F, Sönmez M, Ermantaş N, Özbaş HM, Cansız A, Balc ı M et al. The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene 2016; 586(2): 263-7.
21. Uyar FA, Dorak MT, Saruhan Direskeneli G. Human leuk ocyte antigen A, B and C alleles and human leukocyte antigen haplotypes in Turkey: relationship to other populations. Tissue Antigens 2004; 64(2): 180-7.
22. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomažič J et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6): 568-79.
23. Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 a llele prevalence in HIV-infect ed North American subjects and the impact of allele testing on the in cidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC infectious diseases 2017; 17(1): 1-6.
24. Orkin C, Sadiq ST, Rice L, Jackson F, UK EPI team. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV medicine 2010; 11(3): 187-92.
25. Jilich D, Vraná M, Snopková S, S edlácek D, Kapla J, Rozsypal H et al. Prevalence of human leukocyte antigen HLA- B*57:01 in HIV-infected subjects in the Czech Republic. Cent Eur J Public Health. 2011; 19(3): 128.
26. Deveci A, Çoban AY, Durupınar B. HIV ile Enfekte hastalarda insan lökosit antijeni (HLA)-B*57: 01 prevalansı. Mikrobiyol Bul 2016; 50(4): 544-51.
27. Toplu S, Bayindir Y, Ersoy Y, Memisoglu F, Kose A, Otlu G. Evaluation of HLA-B* 57:01 and its effect on antiretroviral therapy in patients with human immunodeficiency virus infecti on: Experience of a University Hospital. Ann Med Res 2020; 27(12): 3050.
28. Inan D, Sayan M, Deveci A, Ucar F. HLA-B*57:01 Allele prevalence in Turkish HIV infected patients and the value of Real- Time PCR allele testing compored with sequence specific primer technique. HIV Drug Therapy 2020.

APA	GÜLEÇ R, KURTULUŞ M, Arslan F, ÖZYILMAZ B, köse ş (2022). HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. , 249 - 254.
Chicago	GÜLEÇ Rasime Derya,KURTULUŞ Mustafa,Arslan Fatma Demet,ÖZYILMAZ Berk,köse şükran HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. (2022): 249 - 254.
MLA	GÜLEÇ Rasime Derya,KURTULUŞ Mustafa,Arslan Fatma Demet,ÖZYILMAZ Berk,köse şükran HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. , 2022, ss.249 - 254.
AMA	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. . 2022; 249 - 254.
Vancouver	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. . 2022; 249 - 254.
IEEE	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş "HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT." , ss.249 - 254, 2022.
ISNAD	GÜLEÇ, Rasime Derya vd. "HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT". (2022), 249-254.

APA	GÜLEÇ R, KURTULUŞ M, Arslan F, ÖZYILMAZ B, köse ş (2022). HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 26(3), 249 - 254.
Chicago	GÜLEÇ Rasime Derya,KURTULUŞ Mustafa,Arslan Fatma Demet,ÖZYILMAZ Berk,köse şükran HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 26, no.3 (2022): 249 - 254.
MLA	GÜLEÇ Rasime Derya,KURTULUŞ Mustafa,Arslan Fatma Demet,ÖZYILMAZ Berk,köse şükran HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.26, no.3, 2022, ss.249 - 254.
AMA	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2022; 26(3): 249 - 254.
Vancouver	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2022; 26(3): 249 - 254.
IEEE	GÜLEÇ R,KURTULUŞ M,Arslan F,ÖZYILMAZ B,köse ş "HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT." İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 26, ss.249 - 254, 2022.
ISNAD	GÜLEÇ, Rasime Derya vd. "HLA-B VARIATIONS AND HLA-B*57:01 PREVALENCE IN HIV-1 INFECTED TURKISH PATIENT". İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 26/3 (2022), 249-254.